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Kitsada Wudhikarn,1 Claudio G. Brunstein,2 Veronika Bachanova,2
Linda J. Burns,2 Qing Cao,3 Daniel J. Weisdorf2The outcome and management of relapsed lymphoma after allogeneic hematopoietic cell transplantation
(HCT) is difficult. Therapeutic options may include donor lymphocyte infusion (DLI), reduction of immuno-
suppression (RIS), chemotherapy, radiation, immunotherapy, second HCT, and experimental treatments, but
reported data contrasting the response and efficacy of these salvage treatments are limited. We describe the
treatments, response, prognosis, and long-term survival of 72 patients with relapse of lymphoma after allo-
geneic HCT. Between 1991 and 2007, 227 lymphoma patients underwent allogeneic HCT. Of these, 72 (32%)
developed relapse/progression after their HCTat amedian of 99 days (0-1898 days); 37 had early (\100 days)
post-HCTrelapse. Forty-four had non-Hodgkin lymphoma (7 mantle cell, 5 indolent, 15 diffuse large B cell, 4
Burkitt’s, and 13 T/Natural Killer cell), and 28 patients had Hodgkin lymphoma. At the time of HCT, 62 pa-
tients were in remission (22 in complete [CR] and 40 in partial [PR]), 1 had stable whereas 9 had progressive
disease. Seventeen cases received myeloablative and 55 received a reduced-intensity conditioning regimen.
At relapse, most patients had generalized lymphadenopathy, extranodal organ involvement, and advanced dis-
ease. Five patients received no intervention for the post-HCT relapse. Immunosuppressive treatment was
reduced or withdrawn as the first-line therapy in 58 patients (80.5%); 47 were treated using combinations
of conventional chemotherapy (n 5 22), rituximab (n 5 27), interferon (IFN) (n 5 1), DLI (n 5 7), second
HCT (n 5 2), local radiation (n 5 23), and other therapy (n 5 6). Thirty-eight patients had an objective
response (CR in 30, PR in 8), and 2 had stable disease (SD). At the post-HCTrelapse, favorable prognostic
factors for survival after HCT included good ECOG performance status (0-2), normal lactate dehydrogenase
(LDH), early stage disease (stage I-III), isolated extranodal organ involvement, and later relapse (.100 days)
post-HCT. Three-year survival after HCTwas significantly better in late than early relapse (53%; 95% confi-
dence interval [CI] [34%-69%] versus 36%, [20%-52%], P5.02). Of 72 relapsed patients, 29 (40%) survived at
a median of 34 (3-148) months posttransplant. The most common cause of death was underlying lymphoma
(79%). The overall prognosis of relapsed/progressive lymphoma after allogeneic HCT is disappointing, yet half
of patients respond to withdrawal of immunosuppression and additional therapies. Novel treatments can
control lymphoma with acceptable morbidity. Particularly for patients with later relapse, ongoing treatment
after relapse can yield meaningful benefit and prolonged survival.
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Hematopoietic cell transplantation (HCT) has
been widely used as a treatment modality in relapsed
and aggressive lymphoma, most often using an autolo-
gous graft [1-3]. For the past decade, allogeneic HCT,
particularly using reduced-intensity conditioning
(RIC), has become another potential curative treat-
ment option, even in patients with relapse or progres-
sion following autologous HCT [4-7]. However, the
management and outcome of relapse after allogeneic
HCT is uncertain and poorly described [8]. Most
available data are limited to donor lymphocyte infu-
sions (DLI), which sometimes provide durable clinical1497
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of immunosuppression, rituximab, chemotherapy,
radiation, a second allograft, or a combination of
therapies. There are only limited data detailing the
response and efficacy of these salvage treatments in
relapsed lymphoma. Bethge et al. [12] reported on
patients with relapse or progression after nonmyeloa-
blative allogeneic HCT, and in a small cohort, 48%
survived at 24 months following the post-HCT
relapse.We report on the outcome and response to sal-
vage treatment of 72 patients with relapsed lymphoma
following allogeneic HCT.PATIENTS AND METHODS
A total of 227 lymphoma patients underwent allo-
geneic HCT at the University of Minnesota between
January 1991 and December 2007. We identified 72
patients who developed relapsed or progressive disease
afterHCT. Patients’ data were retrieved from theUni-
versity of Minnesota Blood and Marrow Transplanta-
tion Program Database, which contains specified and
prospectively collected data for all patients receiving
transplants at our center. This was supplemented by
detailed review of all treatment and response data
from available medical records. Data and outcomes
were analyzed as of December 2009. Pretransplant
characteristics included age, gender, chemosensitivity,
lymphoma histopathology, and disease status at HCT.
Lymphoma histologies were grouped for analysis as:
indolent lymphoma (chronic lymphocytic leukemia/
small lymphocytic lymphoma, marginal zone lym-
phoma and follicular lymphoma); aggressive lym-
phoma (mantle cell lymphoma, diffuse large B cell
lymphoma (DLBCL), T cell/Natural Killer (T/NK)
cell lymphoma; highly aggressive lymphomas were
Burkitt NHL. Patients underwent allogeneicHCTus-
ing myeloablative or RIC regimens. Graft sources
included bone marrow, filgrastim-mobilized periph-
eral blood (PBSC) from related or unrelated donors
(URD), or unrelated umbilical cord blood (UCB).
In addition to demographics and pre-HCT disease
characteristics, a variety of post-HCT parameters were
considered in univariate analyses to predict outcomes
including: best response achieved from HCT, time to
progression/relapse, relapse sites (nodal and extranodal
organ), numberof nodal area involvement (locoregional
or 1-3 nodal area [stage I-II] versus diffuse or .3
nodal area [stage III]), bulky disease (any tumor mass
.10 cm in diameter; or a mediastinal mass .1/3 chest
diameter), lactate dehydrogenase (LDH) and Eastern
Cooperative Oncology Group (ECOG) performance
status at the time of relapse. Salvage treatments for
relapse/progressive disease after HCT and therapeutic
responses were reviewed. Treatment response was de-
termined by using clinical assessment, biochemical,and radiographic investigation as complete remission
(CR), partial remission (PR), stable disease (SD), or pro-
gressive disease (PD) according to 2007 revised re-
sponse criteria for malignant lymphoma [13]. We
determined the overall survival (OS) after allogeneic
HCT and survival from the time of relapse to last
follow-up or death. Severe treatment-related complica-
tions (equal to or more than grade 3) defined by
National Cancer Institute Common Terminology Cri-
teria for adverse events (CTCAE) version 3.0 were
recorded.
Statistical Analysis
Patients and transplant characteristics between
groupswere comparedusing chi-squareor Fisher’s exact
test for categoric data andWilcoxon’s rank sum test for
continuous data. OS was analyzed by using the Kaplan-
Meier method with 95% confidence intervals (CI) and
comparisons between groups used the log-rank test. All
statistical analyses were performed with Statistical Anal-
ysisSystemstatistical software version9.2 (SAS Institute,
Inc., Cary, NC) with a P value#.05 was considered sta-
tistically significant. Patients and/or their parents/
guardians had exercised written informed consent for
protocol-specified treatment and prospective data col-
lection on their outcomes. TheUniversity ofMinnesota
institutional review board granted specific approval for
this secondary data retrieval and analysis.RESULTS
Pretransplantation Characteristics
Seventy-two patients had relapsed or progressive
lymphoma following allogeneic HCT (Table 1). Me-
dian age at the time ofHCTwas 40 (range: 4-62) years.
Forty-four patients had non-Hodgkin lymphoma
(NHL) (7 mantle cell, 5 follicular/marginal zone/small
lymphocytic/chronic lymphocytic leukemia, 15
DLBCL, 4 Burkitt, and 13 T/NK cell), and 28 had
Hodgkin lymphoma (HL). The median number of
pre-HCT chemotherapeutic regimens was 4 (range:
1-11). Twenty-three patients underwent previous au-
tologous HCT before the allogeneic HCT. At the
time of allogeneic HCT 62 (86%) had chemosensitive
disease (22 were in CR; 40 PR), 1 had stable, and 9
(13%) had progressive disease. Seventeen patients re-
ceived myeloablative and 55 a RIC regimen. UCB
grafts were used more frequently (56%) than sibling
donor granulocyte filgrastim-mobilized PBSC (33%)
and marrow grafts (11%): 4 from siblings and 4 from
URD.
Posttransplantation Relapse or Progression
The median time to post-allogeneic HCT relapse
or progression was 99 days (range: 0-1898 days); 37
Table 1. Characteristics of RelapsedPatients afterAllogeneic
HCT
N 5 72
Median age, years (range) 40 (4-62)
Gender, M/F 42/30
Histopathology
Non-Hodgkin lymphoma 44 (61%)
B cell lymphoma 31 (43%)
Indolent lymphoma* 5 (7%)
Aggressive lymphoma† 22 (30%)
Burkitt’s lymphoma 4 (6%)
T/NK cell lymphoma 13 (18%)
Hodgkin lymphoma 28 (39%)
Median number of regimens before HCT 4 (1-11)
Chemosensitive disease at HCT 62 (86%)
Previous autologous HCT 23 (32%)
Conditioning regimen for allogeneic HCT
Myeloablative 17 (24%)
Reduced intensity 55 (76%)
HCT indicates hematopoietic cell transplantation.
*Indolent lymphoma: chronic lymphocytic leukemia/small lymphocytic
lymphoma, marginal zone lymphoma, and follicular lymphoma.
†Aggressive lymphoma: mantle cell lymphoma (n5 7), diffuse large B cell
lymphoma (n 5 15).
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(within 100 days). Table 2 shows disease characteris-
tics at the time of relapse or progression. Nodal re-
lapse occurred in 65 patients (90%). Of these, 41
patients (57%) had diffuse nodal involvement, and
23 (32%) had bulky disease. Fifty-six patients (78%)
had at least 1 extranodal relapse site (bone marrow
20, lung 27, gastrointestinal 11, musculoskeletal 19,
and central nervous system [CNS] 2). At relapse,
LDH was elevated in 23 of 52 tested (44%). SeventeenTable 2. PresentationofRelapsedandProgressiveLymphoma
after Allotransplantation
N 5 72
Median time to relapse or progression
(days)
99
(range) (interquartile range) (0-1898) (43-194)
N (%)
<100 days 37 (51%)
100-179 days 13 (18%)
180-365 days 15 (20%)
>1 year 7 (10%)
Sites of relapse
Isolated extranodal relapse 7 (10%)
Isolated nodal relapse (Stage I-III) 16 (22%)
Combined nodal and extranodal
(Stage IV)
49 (68%)
Sites of extranodal relapse
Bone marrow 8 (11%)
Visceral 20 (28%)
Musculoskeletal 6 (8%)
Multiorgan involvement 22 (31%)
Performance status (ECOG) at relapse
0-2 55 (76%)
3-4 17 (24%)
Elevated LDH at relapse 23/52 (44%)
ECOG indicates Eastern Cooperative Oncology Group; LDH, lactate
dehydrogenase.patients had poor performance status (ECOG 3 or 4)
at the time of relapse/progression.Treatment of Relapsed Lymphoma
Salvage treatments of relapse/refractory lym-
phoma after allogeneic HCT were tailored individu-
ally based upon the timing of relapse, performance
status, extent of disease, pre-HCT treatment, and un-
derlying comorbidities including active graft-versus-
host disease (GVHD) (Table 3). Five patients received
no intervention at the time of relapse/progression
because of poor performance status or advanced stage
of lymphoma. In 67 patients who received salvage
treatment, reduction of immunosuppression (RIS)
was the first-line therapy in 58 patients (81%) and
was the only initial treatment in 36 patients.
Systemic therapies were used either alone or com-
binedwithother treatment (RIS, chemoimmunotherapy,
or rituximab). Fourteen patients received chemotherapy
alone, 20 had rituximab alone, and 7 had combined
chemoimmunotherapy. Vinca alkaloid (vinblastine/
navelbine)-containing regimens were used most often
(12 patients). Other treatments include interferon
(IFN) (n5 1), secondHCT (n5 2), and novel therapeu-
tic agents (n5 6). DLI (not available for the 40UCB re-
cipients) was given to 7 patients. Local radiation (n5 23)
accompanied RIS and other systemic therapies. One
patient had surgical resection of a mass to relieve
compressive symptoms.Response to Treatment and Survival
Of 67 patients who received treatment for their
relapsed disease, 38 patients had an objective response
(30 CR, 8 PR; overall response rate 52%), whereas 2
had SD and 30 had PD; 2 were not further evaluated.
The median time to best response was 7.1 months
(range: 1-70 months). Of 38 patients who achieved re-
sponse, 24 patients responded (15 CR, 9 PR) to the ini-
tial salvage regimen (RIS [n5 13], combined systemic
treatment [n 5 5], chemotherapy [n 5 2], radiation
[n 5 3], or DLI [n 5 1]). RIS alone induced CR inTable 3. Treatment for Relapse after Allotransplantation
N (%)
No treatment 5 (7%)
Reduction of immunosuppression (RIS) 58 (81%)
Systemic treatment
Chemotherapy 14 (19%)
Rituximab 20 (28%)
Chemotherapy + rituximab 7 (10%)
Interferon 1(1%)
Donor lymphocyte infusion (DLI) 7 (10%)
Involved field radiation 23 (32%)
Surgical resection 1 (1%)
Second allogeneic HCT 2 (3%)
Patients could receive more than 1 treatment; thus, the total is >100%.
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(Table 4). In those who achieved CR, the median
progression-free survival (PFS) was 19 months (range:
0.3-132 days). In 9 patients with PR, the median PFS
was 1.5 months (range: 0.3-4.3 months), but all PR
patients later progressed. Twenty-seven patients
responded to second-line salvage treatment (21 CR, 6
PR) (Table 4). Of 21 patients who received second-
line treatment with chemotherapy, 9 responded (5 PR,
4 CR) and 1 had SD.
The median duration of response from chemo-
therapy was 6 months (range: 2-74 months). Among
9 patients who had an objective response to chemo-
therapy, 5 hadHL, 2T/NK, 1DLBCL, and 1 Burkitt’s
NHL. Six of 9 patients received vinca-alkaloid–
containing regimens. Gemcitabine was used as a single
agent or combined with vinblastine or navelbine in 3
patients. Rituximab, either alone or in combination,
induced response in 12 of 27 (44%) patients (7
DLBCL, 2 follicular, 2 mantle, and 1 HL). Of the 12
patients who responded to rituximab (alone or in com-
bination with other therapies) for their post-HCT re-
lapse, 10 had previously received rituximab, and all but
1 had responded (CR/PR). Rituximab responses for
the post-HCT relapse were modestly durable lasting
1-68 months (median 23 months). Somewhat surpris-Table 4. Response and Survival Following Relapse after Allogeneic
A. All patients
Response to first treatment
CR/PR
SD/PD
Unknown response
Best response achieved
CR/PR
SD
PD
Time to best response after relapse (median range) months
Treatment preceding best response
Reduction of Immunosuppression (RIS)
Chemotherapy
Rituximab
Chemoimmunotherapy
Radiation
Second allogeneic HCT
Donor Lymphocyte Infusion (DLI)
Survival, median (95% CI) months
After HCT
After post-HCT relapse
Early Relapse (<100 Days Post-HCT)
B. Early versus late relapse
3-Year survival following HCT (95% CI) 36% (20%-52%)
3-Year survival following relapse 36%
Best response to treatment*
CR/PR 18 (49%)
SD/PD 18 (49%)
CR indicates complete remission; PR, partial remission; SD, stable disease; PD
transplantion.
*Three patients were not evaluated.ingly, 6 of the 7 (85%) patients who received DLI
achieved remission (4 HL and 2 T/NK cell NHL).
Objective response to any therapy prolonged sur-
vival as the 38 patients who responded (CR/PR) to
post-HCT therapy had median survival of 30 months
(range: 0-150 months) after relapse and 36 months
(range: 3-148 months) after allogeneic HCT
(Figure 1). Patients who did not respond had median
survival of only 2 (0-26 months) months after relapse;
5 months (range: 1-32 months) after HCT.
Twenty-nine patients survive at last follow-up (17
in CR, 2 PR, 3 SD, and 7 PD) (Figure 2). In univariate
analysis, performance status (ECOG PS 3-4 versus
0-2, median survival 1.1 months [95%CI, 0.2-1.9] ver-
sus 18.3 months [17.2-81.2, P\ .001]) and LDH [ele-
vated LDH versus normal LDH, median survival 2.1
months [95% CI 1.3-2.9] versus 9.1 months [14.8-
93], P\ .001]) had a significant and unfavorable im-
pact on OS and also on survival after the post-HCT
relapse (not shown). The pathologic subtype of lym-
phoma had a marginal impact on survival outcome
(P 5 .05) with no survivors in those with Burkitt’s
NHL (Figure 2B). Age (\40 versus$40), chemosensi-
tivity, stem cell source (UCB versus PBSC/BM),
conditioning regimen (myeloablative versus RIC),
and number of treatment regimens prior toHCT
N 5 72
24 (33%)
42 (58%)
6 (8%)
30/8 (42/10%)
2 (3%)
29 (40%)
7.1 (1-70)
30 (42%)
11 (15%)
9 (13%)
9 (13%)
3 (4%)
1 (1%)
5 (7%)
34 (3-148)
25 (0-145)
(n 5 37) Late Relapse ($100 Days post-HCT) (n 5 35) P Value
53% (34%-69%) .02
44% .26
.67
20 (57%)
13 (37%)
, progressive disease; CI, confidence interval; HCT, hematopoeitic cell
Figure 1. (A) OS after allogeneic HCT; (B) 3-year survival following re-
lapse after allogeneic HCT; (C) OS following allogeneic HCT in early
(\100 days) versus late relapse.
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survival after transplant relapse.
Patients with later post-HCT relapse (.100 days)
had better survival than those with early relapse, 3-year
survival 53% versus early relapse 36% (P5 .02) (Table
4B and Figure 1C). In addition to late relapse, patients
who achieved remission (CR/PR), those with stage
I-III disease at relapse or those with isolated nodal or
extranodal disease at relapse had better 3-year survival
after HCT (Figure 2); however, none of these factors
had prognostic impact on survival after transplant re-
lapse. The most common cause of death was because
of underlying lymphoma, which accounted for 79%
of all deaths. Other causes of death included infection(n5 3), severe GVHD (n5 2), diffuse alveolar hemor-
rhage (n 5 1), and liver failure (n 5 1).
Complications Following Treatment of Relapse
Treatment-related adverse events were recorded.
Following treatment of relapse, 13 patients developed
severe cytopenias requiring transfusion or growth fac-
tor support. Severe infection occurred in 12 patients.
Acute GVHD (aGVHD) after RIS or second alloge-
neic HCT was moderate-severe GVHD in only 13 pa-
tients (grade II in 9, grade III-IV in 4). All 7 patients
who received DLI developed aGVHD, but severe
aGVHD (grade III-IV) occurred in only 2 (28%).DISCUSSION
Recurrent lymphomas have become an increasingly
therapeutic challenge. Allogeneic HCT has been more
commonly used as a potential curative option because
of recognition of the graft-versus-lymphoma effect
with recent reports describing improved outcomes
and limited treatment related adverse events [6,14,15].
However, progression or relapse after HCT remains
common and a major cause of death [15]. Importantly,
we found that some patients had prolonged survival fol-
lowing their relapse, particularly those with later
relapse following the allograft. However, the overall
prognosis for our patients with relapsed/progressive
lymphoma following allogeneic HCT is poor, with
a median survival of only 5 months after HCT
(2 months following relapse, similar to the few other
reports) [12,16].
Prognostic factors that modify outcome after alloge-
neic HCT include low transplant comorbidity index
(HCT-CI) scores, conditioning regimen, age, type of
lymphoma, prior cytomegalovirus (CMV) infection,
and graft source [7]. In our study, the major prognostic
factors that determined OS after HCT and survival fol-
lowing relapse include LDH at the time of relapse,
ECOG performance status, stage, and sites of relapse.
The time of relapse after transplantation also affected
posttransplant survival, but not survival after the relapse.
We observed no prognostic impact of graft source, con-
ditioning regimen intensity, or lymphomahistologic sub-
type on survival after transplant relapse. Because of the
small number of patients, multivariate analysis was not
performed. Most earlier reports of allogeneic HCT in
lymphoma [4-7,14,15,17] did not examine postrelapse
management, response, or subsequent survival.
Several brief reports described salvage treatment in
relapsed/progressive lymphoma following HCT;
mostly relapse after autologous HCT [18-27]. A few
series describe allogeneic HCT for those who respond
to other salvage treatments. Reports of salvage
therapies after allogeneic HCT are limited, and there
are no standard guidelines for the treatment of
Figure 2. Survival after allogeneic HCT. (A) Responders CR/PR vsersus SD/PD. (B) Histologic subsets. (C) Stage at relapse (stage I-III versus IV). (D)
Site of relapse (nodes versus extranodal versus combined sites).
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approaches include RIS, chemotherapy, rituximab,
DLI [9,10,28], second allogeneic HCT [29,30],
interleukin-2 [31], or other novel agents [32,33], yet
reported outcomes are disappointing. One small series
described salvage treatment for NHL after autologous
(n5 46) and allogeneic (n5 12)HCT[16].Themedian
survival after allografting was only 7 months, and no
specific therapy was recommended.
Reduction of immunosuppressive is often a first
step inpatientswithout severeGVHDorhighly aggres-
siveNHL [11,34]. In our study, some patientswithHL,
T/NK cell, or mantle cell NHL achieved CR with RIS
alone, whereas indolent B cell lymphoma and highly
aggressive lymphoma such as Burkitt’s lymphoma
rarely responded to RIS, even with other therapies. A
durable response to RIS observed in some patients
might reflect a potent graft-versus-lymphoma effect,
butweobservedno correlationwith specifichistologies.
Rituximab, in addition to its application as an ap-
proved first-line treatment for CD201NHL, has been
increasingly used for relapsed/progressive lymphoma
with promising efficacy and infrequent treatment-
related adverse events [35]. Following HCT, several
studies reported its efficacy as a single agent or in combi-
nation, mostly following autologous HCT [24,36-38].
We observed that rituximab could induce responses in
some patients, even if previously treated with
rituximab. Most of these patients had NHL (DLBCL
7, indolent 2, mantle cell 2) and 1 had HL. However,
no study has prospectively tested rituximab as a salvage
treatment for prevention or therapy of relapse after
allogeneic HCT.
Several chemotherapeutic regimens were used, but
we could not compare the efficacy of different regimensbecause of small numbers and treatment heterogeneity.
Moreover, the selection of chemotherapeutic regimen
was influenced bymany variables including previous re-
sponse, performance status, histopathology, and lym-
phoma burden. Notably, most of the patients in our
series who responded to chemotherapy had HL,
whereas those with NHL rarely responded unless
treated concomitantly with rituximab. It is interesting
to note that chemotherapy plus rituximab provided
a therapeutic effect in this highly refractory patient
subgroup who had exhausted several earlier treatment
modalities. This might reflect a combined graft-
versus-lymphoma effect from the concomitant
reduction in immunosuppression. This was also dem-
onstrated by the promising responses to DLI in our
study. However, this hypothesis will need further re-
search to demonstrate its therapeutic potential.
DLI are used as a rescue treatment in relapsed lym-
phoma following allogeneic HCT with mixed results.
Most early reports of DLI described favorable re-
sponses, but mostly in chronic myeloid leukemia
[39]. Some recent reports include indolent NHL
[10,28]. We observed promising responses after DLI
in 6 of 7 patients including HL and T/NK cell
NHL. In our series, the large number of UCB graft
recipients could not receive DLI.
Second allogeneicHCT for lymphoma is rarely re-
ported and has high treatment-related mortality
[29,30]. This may be because of patients’ poor
performance status, extensive previous treatment,
and refractory disease. Baron et al. [30] reported the
feasibility of RIC allogeneic HCT in patients who
had failed a first myeloablative HCT (autologous or al-
logeneic) with median OS of 813 days. However, the
patients were heterogeneous, and only 10 (of 147)
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NHL or HL. Another series described only modest
morbidity/mortality of second myeloablative alloge-
neic HCT in pediatric patients, especially age \10
years [30]. Recently, Kenkre and colleagues [40] dem-
onstrated promising long-term survival from T cell–
depleted allogeneic HSCT in multiply relapsed
lymphoma. However, there were only 4 patients who
had a prior allotransplant preceding the allogeneic
transplant reported. We might consider that a second
allogeneic transplantation might be a feasible option
if DLI is unavailable.
The prognosis and response to salvage treatment
in relapse/progressive lymphoma following allogeneic
HCT are rarely reported. Acknowledging the limits of
retrospective analysis and heterogeneity of patients,
histologies, and treatments, we are encouraged that
for some patients, especially those with later relapse,
combination approaches can again achieve durable
CR and prolonged survival. Improvements in support-
ive care and development of novel therapies may fur-
ther improve outcome for such patients, but careful
clinical study is needed to dissect the best approaches
and identify those most likely to benefit.ACKNOWLEDGMENTS
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